Omega Diagnostics Group PLC Investor Meeting
February 18 2022 - 2:00AM
RNS Non-Regulatory
TIDMODX
Omega Diagnostics Group PLC
18 February 2022
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Investor Meeting
Omega (AIM: ODX), the specialist medical diagnostics company
focused on industry-leading Health & Nutrition and Global
Health (CD4 and COVID-19) products, announces that, ahead of the
general meeting of the Company to be held on 7 March 2022, Dr Simon
Douglas (Chairman), Jag Grewal (CEO) and Chris Lea (CFO) will
provide a live presentation relating to the Company's recently
announced conditional sale of its Alva facility and new strategic
focus, and also on the possible consequences for the Group should
the resolutions to be proposed at the general meeting in respect of
the proposed placing and open offer by the Company not be
passed.
The presentation will be provided via the Investor Meet Company
platform on Thursday 24 February 2022 at 4:30pm GMT.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 9am the day before the
meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add
to meet OMEGA DIAGNOSTICS GROUP PLC via:
https://www.investormeetcompany.com/omega-diagnostics-group-plc/register-investor
Investors who already follow OMEGA DIAGNOSTICS GROUP PLC on the
Investor Meet Company platform will automatically be invited.
Contacts:
Omega Diagnostics Group PLC www.omegadx.com
Jag Grewal, Chief Executive Officer via Walbrook PR
Chris Lea, Chief Financial Officer
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/Edward Whiley/George Dollemore (Corporate
Finance)
Alice Lane/ Charlotte Sutcliffe
(ECM)
Walbrook PR Limited Tel: 020 7933 8780 or omega@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Applegarth Mob: 07584 391 303
Sam Allen Mob: 07502 558 258
About Omega Diagnostics Group PLC
Omega manufactures and distributes high quality in-vitro
diagnostic products for use in hospitals, clinics, laboratories and
healthcare practitioners in over 75 countries and specialise in the
areas of health and nutrition and global health.
www.omegadx.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABIGDDBBBDGDR
(END) Dow Jones Newswires
February 18, 2022 02:00 ET (07:00 GMT)
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Apr 2024 to May 2024
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From May 2023 to May 2024